Often when a pregnant woman takes a medication, the effects of that medication on her unborn baby’s health are not usually known. This is because pregnant women are often not included in research studies. The EMPRESS Pregnancy Registry will collect information about how pregnancies and babies may, or may not, be affected by ubrogepant, an acute treatment medication for migraine.

During the study, you and your doctor(s) will be asked to share information with the registry team from both you and your baby’s routine doctor appointments. Personal information, such as age, date of birth, and any health information collected about you or your baby, will be kept confidential.

The study begins when you join the Registry and ends one year after childbirth. Participation does not involve any additional doctor's visits or changes to your current treatment plans.

You, or someone you know, may be able to take part if you/they:

• are pregnant

• have been diagnosed with insomnia.

If you are currently pregnant, you do not need to have taken insomnia medication to join. Women who are no longer pregnant but who took QUVIVIQ during or shortly before their pregnancy can also take part.

Join the Registry

Access the Registry on your browser by clicking Web App